Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Ugolini, A., Kenigsberg, M., Rak, A., Vallee, F., Houtmann, J., Lowinski, M., Capdevila, C., Khider, J., Albert, E., Martinet, N., Nemecek, C., Grapinet, S., Bacque, E., Roesner, M., Delaisi, C., Calvet, L., Bonche, F., Semiond, D., Egile, C., Goulaouic, H., Schio, L.(2016) J Med Chem 59: 7066-7074
- PubMed: 27355974 
- DOI: 10.1021/acs.jmedchem.6b00280
- Primary Citation of Related Structures:  
5HLW, 5HO6, 5HNI, 5HOR, 5HOA - PubMed Abstract: 
The HGF/MET pathway is frequently activated in a variety of cancer types. Several selective small molecule inhibitors of the MET kinase are currently in clinical evaluation, in particular for NSCLC, liver, and gastric cancer patients. We report herein the discovery of a series of triazolopyridazines that are selective inhibitors of wild-type (WT) MET kinase and several clinically relevant mutants ...